Programmed cell death 1 (PD1), T cell control of CD28 superfamily members, and PD ligand 1 (PD-L1) are examples of immune checkpoint molecules that have recently been identified as potential targets for CRC immunotherapy [7]. This evidence concerns the gene PDCD1 and colorectal carcinoma.